Biolidics, LC-Bio team up to develop cancer diagnostic solutions

Biolidics will be LC-Bio’s exclusive partner in China for five years.
Biolidics has entered into a collaboration agreement with LC-Bio Technologies, Hangzhou (LC-Bio) to develop cancer diagnostic solutions for a duration of five years, according to an announcement.
Biolidics will be LC-Bio’s exclusive partner in China for the development of the solutions at LC-Bio’s medical laboratory located in Hangzhou. It will be using Biolidics’ proprietary circulating tumour cell technology .
However, the firm may partner with entities other than LC-Bio on the project to develop solutions outside of Zhejiang.
Biolidics will provide all necessary materials and relevant consumables and will be responsible for the market promotion as well as application of the cancer diagnostic solutions once it passes the relevant clinical validation test whilst LC-Bio will be responsible for the issuance of the test result reports in its name and will provide the qualified medical laboratories and space required for the solution.
Both have also agreed to provide any other additional manpower and necessary support for the development and clinical application of the cancer-diagnostic solution.
Biolidics’ board believes that the project is complementary to its core business in the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection, and treatment monitoring.